175 related articles for article (PubMed ID: 27323954)
41. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia.
Kuninaka N; Kurata M; Yamamoto K; Suzuki S; Umeda S; Kirimura S; Arai A; Nakagawa Y; Suzuki K; Kitagawa M
Exp Mol Pathol; 2010 Apr; 88(2):293-8. PubMed ID: 20132814
[TBL] [Abstract][Full Text] [Related]
42. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia.
Mahadevan D; DiMento J; Croce KD; Riley C; George B; Fuchs D; Mathews T; Wilson C; Lobell M
Am J Hematol; 2006 Oct; 81(10):779-86. PubMed ID: 16838325
[TBL] [Abstract][Full Text] [Related]
43. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
[TBL] [Abstract][Full Text] [Related]
44. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
[TBL] [Abstract][Full Text] [Related]
45. Immunoexpression of 5-methylcytosine (5mc) in Bone Marrow Haematopoietic Cells in Patients with Myelodysplastic Syndromes.
Sučić M; Ljubić N; Krmek DŽ; Perković L; Ivanović D; Magazin M; Solomun GF
Ann Clin Lab Sci; 2019 Nov; 49(6):810-817. PubMed ID: 31882433
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Kobayashi S; Ueda Y; Nannya Y; Shibayama H; Tamura H; Ogata K; Akatsuka Y; Usuki K; Ito Y; Okada M; Suzuki T; Hata T; Matsuda A; Tohyama K; Kakumoto K; Koga D; Mitani K; Naoe T; Sugiyama H; Takaku F
Cancer Biomark; 2016 Mar; 17(1):21-32. PubMed ID: 27062571
[TBL] [Abstract][Full Text] [Related]
47. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
48. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome].
Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909
[TBL] [Abstract][Full Text] [Related]
49. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
[TBL] [Abstract][Full Text] [Related]
50. Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
[TBL] [Abstract][Full Text] [Related]
51. [Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
Zhang YZ; Zhao DD; Zhao WP; Zhao HF; Zhao ZG; Wang YF; Wu XX; Han XP; Da WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):108-12. PubMed ID: 22730659
[TBL] [Abstract][Full Text] [Related]
52. [Quantitative study of calcitonin gene methylation in myelodysplastic syndromes].
Bai R; Wu S; Zhu P; Xue H; Xu Y; Qin X
Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):17-20. PubMed ID: 15622744
[TBL] [Abstract][Full Text] [Related]
53. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
55. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
[TBL] [Abstract][Full Text] [Related]
57. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of hyaluronan levels and its pro-osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes.
Fei CM; Guo J; Zhao YS; Zhao SD; Zhen QQ; Shi L; Li X; Chang CK
J Transl Med; 2018 Aug; 16(1):234. PubMed ID: 30143008
[TBL] [Abstract][Full Text] [Related]
59. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
60. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]